Advanced search
Publication Cover
Leukemia & Lymphoma Volume 44, 2003 - Issue 3
Submit an article Journal homepage
101
Views
21
CrossRef citations to date
0
Altmetric
Research Article

High Affinity Molecules Disrupting GRB2 Protein Complexes as a Therapeutic Strategy for Chronic Myelogenous Leukaemia

Stephan M. Feller Cell Signalling Group, Molecular Oncology Laboratory, Cancer Research UK, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
,
Gabriele Tuchscherer Ecole polytechnique fédérale de Lausanne, Institut de chimie moléculaire et biologique (ICMB), EPFL-BCH, Lausanne, Switzerland
&
Jan Voss Department of Neurology, University of Saarland, Homburg/Saar, Germany
Pages 411-427 | Published online: 01 Jul 2009

  • Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R. and Kantarjian, H.M. (1999) "The biology of chronic myeloid leukemia", N. Engl. J. Med. 341, 164-172.
  • Sawyers, C.L. (1999) "Chronic myeloid leukemia", N. Engl. J. Med. 340, 1330-1340.
  • Warmuth, M., Danhauser-Riedl, S. and Hallek, M. (1999) "Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies", Ann. HematoL 78,49-64.
  • Vbss, J., Heisterkamp, N., Groffen, J. and Feller, S.M. (2001) "Leukemic kinases of the AbI family-an update", Signal Transduction 1, 1-26.
  • Demiroglu, A., Steer, E.J., Heath, C., Taylor, K., Bentley, M., Alien, S.L., Kodnru, P., Brody, J.P., Hawson, G., Rodwell, R., Doody, M.L., Camicero, F., Reiter, A., Goldman, J.M., MeIo, J.V. and Cross, N.C. (2001) "The t(8;22) in chronic myeloid leukemia fuses BCR to FGFRl : transforming activity and specific inhibition ofFGERl fusion proteins", Blood 98, 3778-3783.
  • Fioretos, T., Panagopoulos, L, Lassen, C., Swedin, A., Billstrom, R., Isaksson, M., Strombeck, B., Olofsson, T., Mitelman, E and Johansson, B. (2001 ) "Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFRl) genes as a result of t(8;22)(p11 ;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL", Genes Chromosomes Cancer 32, 302-310.
  • Chuang, T.H., Xu, X., Kaartinen, V, Heisterkamp, N., Groffen, J. and Bokoch, G.M. (1995) "Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family", Proc. Natl Acad. Sci. USA 92, 10282-10286.
  • Arlinghaus, R.B. (1998) "The involvement of Bcr in leukemias with the Philadelphia chromosome", Crit. Rev. Oncog. 9, 1-18.
  • Skorski, T., Nieborowska-Skorska, M., Wlodarski, P., Perrotti, D., Martinez, R., Wasik, M.A. and Calabretta, B. (1996) "Elastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase", Proc. Natl Acad. Sci. USA 93, 13137-13142.
  • Guinn, B.A. and Mills, K.I. (1997) "p53 Mutations, methylation and genomic instability in the progression of chronic myeloid leukaemia", Leuk. Lymphoma 26, 211-226.
  • Chopra, R., Pu, Q.Q. and Elefanty, A.G. (1999) "Biology of BCRABL", Blood. Ren 13, 211-229.
  • Ohyashiki, K., Iwama, H., Tauchi, T., Shimamoto, T., Hayashi, S., Ando, K., Kawakubo, K. and Ohyashiki, J.H. (2000) "Telomere dynamics and genetic instability in disease progression of chronic myeloid leukemia", Leuk. Lymphoma 40, 49-56.
  • Pierce, A., Spooncer, E., Wooley, S., Dive, C, Francis, J.M., Miyan, J., Owen-Lynch, P.J., Dexter, T.M. and Whetton, A.D. (2000) "Bcr-AbI protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation", Oncogene 19, 5487-5497.
  • Johansson, B., Fioretos, T. and Mitelman, E (2002) "Cytogenetic and molecular genetic evolution of chronic myeloid leukemia", Acta HaematoL 107, 76-94.
  • Litz, C.E. and Etzell, I. (1998) "Aberrant DNA methylation of genomic regions translocated in myeloid malignancies", Leuk. Lymphoma 30, 1-9.
  • Asimakopoulos, E.A., Shteper, P.J., Krichevsky, S., Fibach, E., Polliack, A., Rachmilewitz, E., Ben-Neriah, Y. and Ben-Yehuda, D. (1999) "ABLl methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia", Blood 94, 2452-2460.
  • Cohen, N., Rozenfeld-Granot, G., Harden, I., Brok-Simoni, E, Amariglio, N., Rechavi, G. and Trakhtenbrot, L. (2001) "Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to Interferon therapy, and poor prognosis", Cancer Genet. Cytogenet. 128, 114-119.
  • Huntly, B.J., Reid, A.G., Bench, A.J., Campbell, L.J., Telford, N., Shepherd, P., Szer, J., Prince, H.M., Turner, P., Grace, C., Nacheva, E.P. and Green, A.R. (2001) "Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia", Blood 98, 1732-1738.
  • O'Dwyer, M.E., Mauro, M.J. and Druker, B.J. (2002) "Recent advancements in the treatment of chronic myelogenous leukemia", Annu. Rev. Med. 53, 369-381.
  • Talpaz, M., Silver, R.T., Druker, B.J., Goldman, I.M., GambacottiPasserini, C., Guilhot, E, Schiffer, C.A., Fischer, T., Deininger, M. W., Lennard, A.L., Hochhaus, A., Ottmann, O.G., Gratwohl, A., Baccarani, M., Stone, R., Tura, S., Mahon, EX., Fernandes-Reese, S., Gathmann, L, Capdeville, R., Kantarjian, H.M. and Sawyers, C.L. (2002) "Imatinib induces durable hematologie and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study", Blood 99, 1928-1937.
  • Zhao, X., Ghaffari, S., Lodish, H., Malashkevich, V.N. and Kim, P.S. (2002) "Structure of the Bcr-Abl oncoprotein oligomerization domain", Nat. Struct. Biol. 9, 117-120.
  • Le, L.Q., Kabarowski, J.H., Wong, S., Nguyen, K., Gambhir, S.S. and Witte, O.N. (2002) "Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene", Cancer Cell 1, 381-391.
  • Slupianek, A., Schmutte, C., Tombline, G., Nieborowska-Skorska, M., Hoser, G., Nowicki, M.O., Pierce, A.J., Fishel, R. and Skorski, T. (2001) "BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance", Mol. Cell. 8, 795-806.
  • Huettner, C.S., Zhang, P., Van Etten, R.A. and Tenen, D.G. (2000) "Reversibility of acute B-cell leukaemia induced by BCRABLl", Nat. Genet. 24, 57-60.
  • Li, S., Earia, Jr., R.L., Million, R.P., Daley, G.Q. and Van Etten, R.A. (1999) "The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity", J. Exp. Med. 189, 1399-1412.
  • Ghaffari, S., Daley, G.Q. and Lodish, H.F. (1999) "Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays", Leukemia 13, 1200-1206.
  • Van Etten, R.A. (2001) "Pathogenesis and treatment of Ph+ leukemia: recent insights from mouse models", Curr. Opin. Hematol. 8, 224-230.
  • Wong, S. and Witte, O.N. (2001) "Modeling Philadelphia chromosome positive leukemias", Oncogene 20, 5644-5659.
  • Bernardi, R., Grisendi, S. and Pandolfi, PP. (2002) "Modelling haematopoietic malignancies in the mouse and therapeutical implications", Oncogene 21, 3445-3458.
  • Holtschke, T., Lohler, J., Kanno, Y., Fehr, T., Giese, N., Rosenbauer, F., Lou, J., Knobeloch, K.P., Gabriele, L., Waring, J.F., Bachmann, M.F., Zinkemagel, R.M., Morse, 3rd, H.C., Ozato, K. and Horak, L (1996) "Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene", Cell 87, 307-317.
  • Passegue, E., Jochum, W, Schorpp-Kistner, M., Mohle-Steinlein, U. and Wagner, E.F. (2001) "Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage", Cell 104, 21-32.
  • Helgason, C.D., Damen, J.E., Rosten, P., Grewal, R., Sorensen, P., Chappel, S.M., Borowski, A., link, F., Krystal, G. and Humphries, R.K. (1998) 'Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span", Genes Den 12, 1610-1620.
  • Sattler, M, Verma, S., Byrne, C.H., Shrikhande, G., Winkler, T., Algate, P.A., Rohrschneider, L.R. and Griffin, I.D. (1999) "BCR/ABL directly inhibits expression of SHIP, an SH2containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis", MoI. Cell. Biol. 19, 7473-7480.
  • Di Cristofano, A., Niki, M., Zhao, M., Karnell, F.G., Clarkson, B., Pear, W.S., Van Aelst, L. and Pandolfi, PP. (2001) "p62(dok), A negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl)", J. Exp. Med. 194, 275-284.
  • Schmidt, M., Nagel, S., Proba, I., Thiede, C., Ritter, M., Waring, J.F., Rosenbauer, F., Huhn, D., Wittig, B., Horak, I. and Neubauer, A. (1998) "Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias", Blood 91, 22-29.
  • Schmidt, M., Hochhaus, A., Kitsche, A., Hehlmann, R. and Neubauer, A. (2001) "Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha", Blood 97, 3648-3650.
  • Gabriele, L., Phung, I., Fukumoto, I., Segal, D., Wang, I.M., Giannakakou, P., Giese, N.A., Ozato, K. and Morse, 3rd, H.C. (1999) "Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein", J. Exp. Med. 190,411 -421.
  • Hao, S.X. and Ren, R. (2000) "Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Ablinduced myeloproliferative disorder", MoI. Cell. Biol. 20, 1149-1161.
  • Deng, M. and Daley, G.Q. (2001) "Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia", Blood 97, 3491-3497.
  • Rosenbauer, F., Rallies, A., Scheller, M., Knobeloch, K.P., Rock, C.O., Schwieger, M., Stocking, C. and Horak, L (2002) "Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion", EMBO J. 21, 211-220.
  • Feller, S.M., Posern, G., Voss, J., Kardinal, C., Sakkab, D., Zheng, I. and Knudsen, B.S. (1998) "Physiological signals and oncogenesis mediated through Crk family adapter proteins", J. CeIl. Physiol. 177, 535-552.
  • Sattler, M. and Salgia, R. (1998) "Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells", Leukemia 12, 637-644.
  • Nichols, G.L., Raines, M.A., Vera, J.C., Lacomis, L., Tempst, P. and Golde, D.W. (1994) "Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells", Blood 84, 2912-2918.
  • Oda, T., Heaney, C., Hagopian, J.R., Okuda, K., Griffin, J.D. and Druker, B.J. (1994) "Grid is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia", J. Biol Chem. 269, 22925-22928.
  • ten Hoeve, J., Arlinghaus, R.B., Guo, I.Q., Heisterkamp, N. and Groffen, I. (1994) "Tyrosine phosphorylation of CRKL in Philadelphia + leukemia", Blood 84, 1731 -1736.
  • Golub, T.R., Slonim, D.K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J.P., Coller, H., Loh, M.L., Downing, I.R., Caligiuri, M.A., Bloomfield, CD. and Lander, E.S. (1999) "Molecular classification of cancer: class discovery and class prediction by gene expression monitoring", Science 286, 531-537.
  • Ohmine, K., Ota, J., Ueda, M, Ueno, S., Yoshida, K., Yamashita, Y, Kirito, K., Imagawa, S., Nakamura, Y, Saito, K., Akutsu, M., Mitani, K., Kano, Y, Komatsu, N., Ozawa, K. and Mano, H. (2001) "Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells", Oncogene 20, 8249-8257.
  • Radich, I.P. (2002) "The promise of gene expression analysis in hematopoetic malignancies", Biochim. Biophys. Acta 1602, 88-95.
  • Mandanas, R.A., Leibowitz, D.S., Gharehbaghi, K., Tauchi, T., Burgess, G.S., Miyazawa, K., Jayaram, H.N. and Boswell, H.S. (1993) "Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells", Blood 82, 1838-1847.
  • Skorski, T., Kanakaraj, P., Ku, D.H., Nieborowska-Skorska, M., Canaani, E., Zon, G., Perussia, B. and Calabretta, B. (1994) "Negative regulation of p 120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth", J. Exp. Med. 179, 1855-1865.
  • Cortez, D., Stoica, G., Pierce, J.H. and Pendergast, A.M. (1996) "The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway", Oncogene 13, 2589-2594.
  • Raitano, A.B., Whang, YE. and Sawyers, CL. (1997) "Signal transduction by wild-type and leukemogenic AbI proteins", Biochim. Biophys. Acta 1333, F201-F216.
  • Voss, J., Posern, G., Hannemann, I.R., Wiedemann, L.M., Turban, A.G., Poirel, H., Bernard, O.A., Adermann, K., Kardinal, C. and Feller, S.M. (2000) "The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways", Oncogene 19, 1684-1690.
  • Liu, E., Hjelle, B. and Bishop, J.M (1988) 'Transforming genes in chronic myelogenous leukemia", Proc. Natl Acad. Sci. USA 85, 1952-1956.
  • Cogswell, P.C., Morgan, R., Dunn, M., Neubauer, A., Nelson, P., Poland-Johnston, N.K., Sandberg, A.A. and Liu, E. (1989) "Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia", Blood 74, 2629-2633.
  • Collins, S.J., Howard, M., Andrews, D.F., Agura, E. and Radich, J. (1989) "Rare occurrence of N-ras point mutations in Philadelphia chromosome positive chronic myeloid leukemia", Blood 73, 1028-1032.
  • LeMaistre, A., Lee, M.S., Talpaz, M., Kantarjian, H.M., Freireich, E.J., Deisseroth, A.B., Trujillo, I.M. and Stass, S.A. (1989) "Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia", Blood 73, 889-891.
  • Serra, A., Guerrasio, A., Gaidano, G., Rosso, C., Rege-Cambrin, G., Petroni, D., Mazza, U. and Saglio, G. (1993) "Molecular defects associated with the acute phase CML", Leak. Lymphoma 11(Suppl. 1), 25-28.
  • Kolch, W. (2000) "Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions", Biochem. J. 351(Pt 2), 289-305.
  • Shields, J.M., Pruitt, K., McFaIl, A., Shaub, A. and Der, C.J. (2000) "Understanding Ras: 'it ain't over 'til it's over'", Trends CeIl. Biol. 10, 147-154.
  • Lee, Jr., J.T. and McCubrey, J.A. (2002) "The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia", Leukemia 16, 486-507.
  • Reichert, A., Heisterkamp, N., Daley, G.Q. and Groffen, I. (2001) 'Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in Pl 90 transgenic mice with the farnesyl transferase inhibitor SCH66336",. Stood 97, 1399-1403.
  • Kardinal, C., Konkol, B., Schulz, A., Posern, G., Lin, H., Adermann, K., Eulitz, M., Estrov, Z., Talpaz, M., Arlinghaus, R.B. and Feller, S.M. (2000) "Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients", FASEB J. 14, 1529-1538.
  • Feller, S.M. (2001) "Crk family adaptors-signalling complex formation and biological roles", Oncogene 20, 6348-6371.
  • Kardinal, C., Konkol, B., LJn, H., Eulitz, M, Schmidt, E.K., Estrov, Z., Talpaz, M., Arlinghaus, R.B. and Feller, S.M. (2001) "Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes", Blood 98, 1773-1781.
  • Skorski, T., Nieborowska-Skorska, M., Szczylik, C., Kanakaraj, P., Perrotti, D., Zon, G., Gewirtz, A., Perussia, B. and Calabretta, B. (1995) "C-RAF-I serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis", Cancer Res. SS, 2275-2278.
  • Salomoni, P., Wasik, M.A., Riedel, R.F., Reiss, K., Choi, J.K., Skorski, T. and Calabretta, B. (1998) "Expression of constitua vely active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant", J. Exp. Med 187, 1995-2007.
  • Neshat, M.S., Raitano, A.B., Wang, H.G., Reed, J.C. and Sawyers, C.L. (2000) "The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and independent pathways: roles for phosphatidylinositol 3-kinase and Raf', MoI. Cell. Biol. 20, 1179-1186.
  • Yu, C., Krystal, G., Varticovksi, L., McKinstry, R., Rahmani, M., Dent, P. and Grant, S. (2002) "Pharmacologie mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STT571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells", Cancer Res. 62, 188-199.
  • Datta, S.R., Brunei, A. and Greenberg, M.E. (1999) "Cellular survival: a play in three Akts", Genes Den 13, 2905-2927.
  • Stein, R.C. and Waterfield, M.D. (2000) "PI3-kinase inhibition: a target for drug development?", MoI. Med. Today 6, 347-357.
  • Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, I. and Waterfield, M.D. (2001) "Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer", Anna. Rev. Cell. Dev. Biol. 17, 615-675.
  • Skorski, T., Kanakaraj, P., Nieborowska-Skorska, M., Ratajczak, M.Z., Wen, S.C., Zon, G., Gewirtz, A.M., Perussia, B. and Calabretta, B. (1995) "Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells", Blood 86, 726-736.
  • Calabretta, B. and Skorski, T. (1996) "BCR/ABL regulation of PI-3 kinase activity", Leak. Lymphoma 23,473-476.
  • Skorski, T., Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R., Choi, J.K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, TO., Wasik, M.A., Tsichlis, P.N. and Calabretta, B. (1997) 'Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway", EMBO J. 16, 6151-6161.
  • Griffin, I.D. (2001) "Phosphatidyl inositol signaling by BCR/ABL: opportunities for drug development", Cancer Chemother. Pharmacol. 48(Suppl. 1), S11-S16.
  • Zimmermann, S. and Moelling, K. (1999) "Phosphorylation and regulation of Raf by Akt (protein kinase B)", Science 286, 1741-1744.
  • Chan, T.O., Rodeck, U., Chan, A.M., Kimmelman, A.C., Rittenhouse, S.E., Panayotou, G. and Tsichlis, RN. (2002) "Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit", Cancer Cell 1, 181-191.
  • Vazquez, F. and Sellers, W.R. (2000) "The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling", Biochim. Biophys. Acta 1470, M21-M35.
  • Maehama, T, Taylor, G.S. and Dixon, I.E. (2001) "PTEN and myotubularin: novel phosphoinositide phosphatases", Annu. Rev. Biochem. 70, 247-279.
  • Aggerholm, A., Gronbaek, K., Guldberg, P. and Hokland, P. (2000) "Mutational analysis of the tumour suppressor gene MMACl/ PTEN in malignant myeloid disorders", EUT. J. Haematol. 65, 109-113.
  • Rohrschneider, L.R., Fuller, I.F., Wolf, I., Liu, Y. and Lucas, D.M. (2000) "Structure, function, and biology of SHIP proteins", Genes Den 14, 505-520.
  • Bowman, T., Garcia, R., Turkson, J. and Jove, R. (2000) "STATs in oncogenesis", Oncogene 19, 2474-2488.
  • Bromberg, J. and Darnel), Jr., J.E. (2000) "The role of STATs in transcriptional control and their impact on cellular function", Oncogene 19, 2468-2473.
  • Lin, T.S., Mahajan, S. and Frank, D.A. (2000) "STAT signaling in the pathogenesis and treatment of leukemias", Oncogene 19, 2496-2504.
  • Buettner, R., Mora, L.B. and Jove, R. (2002) "Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention", Clin. Cancer Res. 8, 945-954.
  • O'Shea, J.J., Gadina, M. and Schreiber, R.D. (2002) "Cytokine signaling in 2002:new surprises in the Jak/Stat pathway", Cell 109(Suppl.), S121-S131.
  • de Groot, R.P., Raaijmakers, J.A., Lammers, J.W., Jove, R. and Kbenderman, L. (1999) "STAT5 activation by BCR-AbI contributes to transformation of K562 leukemia cells", Blood 94, 1108-1112.
  • Nieborowska-Skorska, M., Wasik, M.A., Slupianek, A., Salomoni, P., Kitamura, T, Calabretta, B. and Skorski, T. (1999) "Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis", J. Exp. Med. 189, 1229-1242.
  • Gesbert, F. and Griffin, J.D. (2000) "Bcr/Abl activates transcription of the BcI-X gene through STAT5", Blood 96, 2269-2276.
  • Horita, M., Andreu, E.J., Benito, A., Arbona, C., Sanz, C., Benet, I., Prosper, F. and Fernandez-Luna, J.L. (2000) "Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL", J. Exp. Med 191, 977-984.
  • Hoover, R.R., Gerlach, M.J., Koh, E.Y. and Daley, G.Q. (2001) "Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells", Oncogene 20, 5826-5835.
  • Nieborowska-Skorska, M., Hoser, G., Kossev, P., Wasik, M.A. and Skorski, T. (2002) "Complementary functions of the antiapoptotic protein Al and serine/threonine kinase pim-1 in the BCR/ABLmediated leukemogenesis", Blood 99, 4531-4539.
  • Sexl, V, Piekorz, R., Moriggl, R., Rohrer, J., Brown, M.P., Bunting, K.D., Rothammer, K., Roussel, M.F. and IhIe, J.N. (2000) "Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5", Blood 96, 2277-2283.
  • Schwaller, J., Parganas, E., Wang, D., Cain, D., Aster, J.C., Williams, I.R., Lee, C.K., Gerthner, R., Kitamura, T, Frantsve, J., Anastasiadou, E., Loh, M.L., Levy, D.E., IhIe, J.N. and Gilliland, D.G. (2000) "Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2", MoL Cell. 6, 693-704.
  • Goldman, J.M. and Druker, B.J. (2001) "Chronic myeloid leukemia: current treatment options", Blood 98, 2039-2042.
  • Savage, D.G. and Antman, K.H. (2002) "Imatinib mesylate--a new oral targeted therapy", N. Engl. J. Med. 346, 683-693.
  • Bonifazi, F., de Vivo, A., Rosti, G., Guilhot, F., Guilhot, J., Trabacchi, E., Hehlmann, R., Hochhaus, A., Shepherd, P.C., Steegmann, J.L., Kluin-Nelemans, H.C., Thaler, J., Simonsson, B., Louwagie, A., Reiffers, J., Mahon, EX., Montefusco, E., Alimena, G., Hasford, J., Richards, S., Saglio, G., Testoni, N., Martinelli, G., Tura, S. and Baccarani, M. (2001) "Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders", Blood 98, 3074-3081.
  • Talpaz, M. (2001) "Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition", Semin. Hematol. 38, 22-27.
  • Kirkwood, J. (2002) "Cancer immunotherapy : the interferon-alpha experience", Semin. Oncol. 29, 18-26.
  • Buchdnnger, E., Zimmermann, I., Mett, H., Meyer, T., Muller, M., Druker, B.J. and Lydon, N.B. (1996) "Inhibition of the AbI protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative", Cancer Res. 56, 100-104.
  • Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J. and Lydon, N.B. (1996) "Effects of a selective inhibitor of the AbI tyrosine kinase on the growth of BerAbI positive cells", Nat. Med. 2, 561-566.
  • Druker, B.I. (2002) "Perspectives on the development of a molecularly targeted agent", Cancer Cell I, 31 -36.
  • Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B. and Kuriyan, J. (2000) "Structural mechanism for STI-571 inhibition of abelson tyrosine kinase", Science 289, 1938-1942.
  • Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.I., Reese, S.F., Ford, J.M., Capdeville, R. and Talpaz, M. (2001) "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome", N. Engl. J. Med. 344, 1038-1042.
  • Druker, B.J., Talpaz, M., Resta, D.I., Peng, B., Buchdunger, E, Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., OhnoIones, S. and Sawyers, C.L. (2001) "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia", N. Engl. J. Med. 344, 1031-1037.
  • Sawyers, C.L., Hochhaus, A. Feldman, E., Goldman, J.M., Miller, C.B., Ottmann, O.G., Schiffer, C.A., Talpaz, M., Guilhot, E, Deininger, M.W., Fischer, T., O'Brien, S.G., Stone, R.M., Gambacorti-Passerini, C.B., Russell, N.H., Reiffers, J.J., Shea, T.C., Chapuis, B., Coutre, S., Tura, S., Morra, E, Larson, R.A., Saven, A., Peschel, C., Gratwohl, A. Mandelli, F., Ben-Am, M., Gathmann, I., Capdeville, R., Paquette, R.L. and Druker, B.I. (2002) "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study", Blood 99, 3530-3539.
  • Gone, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N. and Sawyers, C.L. (2001) "Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification", Science 293, 876-880.
  • Krystal, G.W. (2001) "Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents", Drug Resist. Updates 4, 16-21.
  • Sawyers, C.L. (2001) "Research on resistance to cancer drug Gleevec", Science 294, 1834.
  • Gone, M.E. and Sawyers, C.L. (2002) "Molecular mechanisms of resistance to STI-571 in chronic myeloid leukemia", Curr. Opin. Hematol. 9, 303-307.
  • Corbin, A.S., Buchdunger, E., Pascal, F. and Druker, B.I. (2002) "Analysis of the structural basis of specificity of inhibition of the AbI kinase by STI-571", J. Biol. Chem. 277, 32214-32219.
  • Andersen, M.K., Pedersen-Bjergaard, I., Kjeldsen, L., Dufva, I.H. and Brondum-Nielsen, K. (2002) "Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8", Leukemia 16, 1390-1393.
  • Hofmann, W.K., de Vos, S., Elashoff, D., Gschaidmeier, H., Hoelzer, D., Kbeffler, H.P. and Ottmann, O.G. (2002) "Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STT571 and gene-expression profiles: a gene-expression study", Lancet 359,481-486.
  • Graham, S.M., Iorgensen, H.G., Allan, E, Pearson, C., Alcorn, MJ., Richmond, L. and Holyoake, T.L. (2002) "Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STT571 in vitro", Blood 99, 319-325.
  • Ebnoether, M., Stentoft, J., Ford, J., Buhl, L. and Gratwohl, A. (2002) "Cerebral oedema as possible complication of treatment with imatinib", Lancet 359, 1751-1752.
  • Buchdunger, E., Cioffi, C.L., Law, N., Stover, D., Ohno-Jones, S., Druker, B.J. and Lydon, N.B. (2000) "AbI protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors", J. Pharmacol. Exp. Ther. 295, 139-145.
  • Heinrich, M.C., Griffith, D.J., Draker, B.J., Wait, C.L., Ott, K.A. and Zigler, A.J. (2000) "Inhibition of c-kit receptor tyrosine kinase activity by STT571, a selective tyrosine kinase inhibitor", Blood 96, 925-932.
  • Okuda, K., Weisberg, E., Gilliland, D.G. and Griffin, I.D. (2001) "ARG tyrosine kinase activity is inhibited by 811571", Blood 97, 2440-2448.
  • Krystal, G.W., Honsawek, S., Litz, J. and Buchdunger, E. (2000) "The selective tyrosine kinase inhibitor STT571 inhibits small cell lung cancer growth", Clin. Cancer Res. 6, 3319-3326.
  • Wang, W.L., Healy, M.E., Sattler, M., Verraa, S., Lin, J., Maulik, G., Stiles, C.D., Griffin, I.D., Johnson, B.E. and Salgia, R. (2000) "Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI571", Oncogene 19, 3521-3528.
  • Joensuu, H., Roberts, P.J., Sarlomo-Rikala, M., Andersson, L.C., Tervahartiala, P., Tuveson, D., Silberman, S., Capdeville, R., Dimitrijevic, S., Druker, B. and Demetri, G.D. (2001) "Effect of the tyrosine kinase inhibitor STT571 in a patient with a metastatic gastrointestinal stromal tumor", N. Engl. J. Med. 344, 1052-1056.
  • van Oosterom, A.T., Judson, I., Verweij, J., Stroobants, S., Donate di Paola, E., Dimitrijevic, S., Martens, M, Webb, A., Sciot, R., Van Glabbeke, M., Silberman, S. and Nielsen, O.S. (2001) "Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study", Lancet 358, 1421-1423.
  • Heinrich, M.C., Blanke, C.D., Druker, B.J. and Corless, C.L. (2002) "Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies", J. Clin. Oncol. 20, 1692-1703.
  • Radford, LR. (2002), Imatinib. Novartis. Curr. Opin. Investig. Drugs 3, 492-499.
  • Thiesing, J.T., Ohno-Jones, S., Kolibaba, K.S. and Druker, B.J. (2000) "Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-ablpositive cells", Blood 96, 3195-3199.
  • Kano, Y., Akutsu, M., Tsunoda, S., Mano, H., Sato, Y., Honma, Y. and Furukawa, Y. (2001) "In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents", Blood 97, 1999-2007.
  • Topaly, J., Zeller, W.J. and Fruehauf, S. (2001) "Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells", Leukemia 15, 342-347.
  • Marley, S.B., Davidson, R.J., Goldman, J.M. and Gordon, M.Y. (2002) "Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia", Br. J. Haematol. 116, 162-165.
  • La Rosee, P., O'Dwyer, M.E. and Druker, B.J. (2002) "Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective", Leukemia 16, 1213-1219.
  • Mauro, M.J., O'Dwyer, M., Heinrich, M.C. and Druker, B.J. (2002) "STI571: a paradigm of new agents for cancer therapeutics", J. Clin. Oncol. 20, 325-334.
  • O'Dwyer, M. (2002) "Multifaceted approach to the treatment of bcr-abl-positive leukemias", Oncologist 7(Suppl. 1), 30-38.
  • Kwong, Y.L. and Todd, D. (1997) "Delicious poison: arsenic trioxide for the treatment of leukemia", Blood 89, 3487-3488.
  • O'Dwyer, M.E., Rosee, P.L., Nimmanapalli, R., Bhalla, K.M. and Druker, B.J. (2002) "Recent advances in Philadelphia chromosome-positive malignancies: The potential role of arsenic trioxide", Semin. Hematol. 39, 18-213.
  • Perkins, C., Kim, C.N., Fang, G. and Bhalla, K.N. (2000) "Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or BcI-X(L)", Blood 95, 1014-1022.
  • Puccetti, E., Culler, S., Orieth, A., Bruggenolte, N., Hoelzer, D., Ottmann, O.G. and Ruthardt, M. (2000) "BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity", Cancer Res. 60, 3409-3413.
  • Porosnicu, M., Nimmanapalli, R., Nguyen, D., Worthington, E., Perkins, C. and Bhalia, K.N. (2001) "Co-treatment with As203 enhances selective cytotoxic effects of STI-571 against Brc-Abl- positive acute leukemia cells", Leukemia 15, 772-778.
  • Vigneri, P. and Wang, J.Y. (2001) "Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase", Nat. Med. 7, 228-234.
  • Wang, J.Y. (2000) "Regulation of cell death by the AbI tyrosine kinase", Oncogene 19, 5643-5650.
  • Miller, J.S. (1998) "Innovative therapy for chronic myelogenous leukemia", Hematol Oncol. Clin. North Am. 12, 173-206.
  • Gewirtz, A.M. (1999) 'Oligonucleotide therapeutics: clothing the emperor", Curr. Opin. Mol. Ther. 1, 297-306.
  • Verfaillie, C.M., Mclvor, R.S. and Zhao, R.C. (1999) "Gene therapy for chronic myelogenous leukemia", MoI. Med. Today S, 359-366.
  • Clark, R.E. (2000) "Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems", Leukemia 14, 347-355.
  • Tanabe, T., Kuwabara, T., Warashina, M., Tani, K., Taira, K. and Asano, S. (2000) "Oncogene inactivation in a mouse model", Nature 406, 473-474.
  • Danhauser-Riedl, S., Warmuth, M., Druker, B.J., Emmerich, B. and Hallek, M. (1996) "Activation of Src kinases p53/561yn and p59hck by p210bcr/abi in myeloid cells", Cancer Res. 56, 3589-3596.
  • Don, Q.P., McGuire, T.F., Peng, Y. and An, B. (1999) "Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells", J. Pharmacol. Exp. Ther. 289, 781-790.
  • Hoppe-Seyler, F. and Butz, K. (2000) "Peptide aptamers: powerful new tools for molecular medicine", J. MoL Med. 78, 426-430.
  • Nishikura, K. (2001) "A short primer on RNAi: RNA-directed RNA polymerase acts as a key catalyst", Cell 107, 415-418.
  • Hutvagner, G. and Zamore, P.D. (2002) "RNAi: nature abhors a double-strand", Curr. Opin. Genet. Dev. 12, 225-232.
  • KoIb, H.J., Mittermuller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M. and Wilmanns, W. (1990) "Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients", Blood 76, 2462-2465.
  • Cullis, J.O., Jiang, Y.Z., Schwerer, A.P., Hughes, T.P., Barren, AJ. and Goldman, J.M. (1992) "Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation", Blood 79, 1379-1381.
  • Dazzi, F. and Goldman, J.M. (1998) "Adoptive immunotherapy following allogeneic bone marrow transplantation", Annu. Ren Med. 49, 329-340.
  • Choudhury, A., Toubert, A., Sutaria, S., Charron, D., Champlin, R.E. and Claxton, D.F. (1998) "Human leukemia-derived dendritic cells: ex-vivo development of specific antileukemic cytotoxicity", CrIt. Rev. Immunol. 18, 121-131.
  • Pinilla-Ibarz, I., Cathcart, K., Korontsvit, T., Soignet, S., Bocchia, M., Caggiano, J., Lai, L., limenez, I., Kolitz, J. and Scheinberg, D.A. (2000) "Vaccination of patients with chronic myelogenous leukemia with bcr-abi oncogene breakpoint fusion peptides generates specific immune responses", Blood 95, 1781-1787.
  • Pinilla-Ibarz, J., Cathcart, K. and Scheinberg, D.A. (2000) "CML vaccines as a paradigm of the specific immunotherapy of cancer", Blood Rev. 14,111-120.
  • Sun, J.Y., Krouse, R.S., Forman, S.J., Senitzer, D., Sniecinski, L, Chatterjee, S. and Wong, Jr, K.K. (2002) "Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro", Cancer Res. 62, 3175-3183.
  • Kuriyan, I. and Cowburn, D. (1997) "Modular peptide recognition domains in eukaryotic signaling", Annu. Rev. Biophys. Biomol. Struct. 26, 259-288.
  • Pawson, T. and Scott, I.D. (1997) "Signaling through scaffold, anchoring, and adaptor proteins", Science 278, 2075-2080.
  • Mayer, B.J. and Gupta, R. (1998) "Functions of SH2 and SH3 domains", Curr. Top. Microbiol. Immunol. 228, 1 -22.
  • Buday, L. (1999) "Membrane-targeting of signaling molecules by SH2/SH3 domain-containing adaptor proteins", Biochim Biophys. Ada 1422, 187-204.
  • Bakal, C.J. and Davies, I.E. (2000) "No longer an exclusive club: eukaryotic signaling domains in bacteria", Trends Cell. Biol. 10, 32-38.
  • Pawson, T. and Nash, P. (2000) "Protein-protein interactions define specificity in signal transduction", Genes Dev. 14, 1027-1047.
  • Gmeiner, W.H. and Horita, D.A. (2001) "Implications of SH3 domain structure and dynamics for protein regulation and drug design", CeIl. Biochem. Biophys. 35, 127-140.
  • Mayer, B.I. (2001) "SH3 domains: complexity in moderation", J. Cell. Sci. 114, 1253-1263.
  • Brugge, I.S. (1993) "New intracellular targets for therapeutic drug design", Science 260, 918-919.
  • Smithgall, T.E. (1995) "SH2 and SH3 domains: potential targets for anti-cancer drug design", J. Pharmacol. Toxicol. Methods 34, 125-132.
  • Vidai, M., Gigoux, V. and Garbay, C. (2001) "SH2 and SH3 domains as targets for anti-proliferative agents", Crit. Rev. Oncol. Hematol. 40, 175-186.
  • Cody, W.L., Lin, Z., Panek, R.L., Rose, D.W. and Rubin, I.R. (2000) "Progress in the development of inhibitors of SH2 domains", Curr. Pharm Des. 6, 59-98.
  • Shakespeare, W.C. (2001) "SH2 domain inhibition: a problem solved?", Curr. Opin. Chem. Biol. 5, 409-415.
  • Liu, S.K., Berry, D.M. and McGlade, C.J. (2001) "The role of Gads in hematopoietic cell signalling", Oncogene 20,6284-6290.
  • Cheng, A.M., Saxton, T.M., Sakai, R., Kulkarn, S., Mbamalu, G., Vogel, W., Tortorice, C.G., Cardiff, R.D., Cross, I.C., Muller, W.J. and Pawson, T. (1998) "Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation", Cell 95, 793-803.
  • Songyang, Z., Shoelson, S.E., McGlade, I., Olivier, P., Pawson, T., Bustelo, X.R., Barbacid, M., Sabe, H., Hanafusa, H., Yi, T., et al (1994) "Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav", MoI. Cell. Biol. 14, 2777-2785.
  • Adzhubei, A.A. and Stemberg, M.I. (1993) "Left-handed polyproline II helices commonly occur in globular proteins", J. Mol. Biol 229, 472-493.
  • Lim, W.A., Richards, P.M. and Fox, R.O. (1994) "Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains", Nature 372, 375-379.
  • Zarich, N., Oliva, I.L., Jorge, R., Santos, E. and Rojas, I.M. (2000) "The isoform-specific stretch of hSosl defines a new Grb2-binding domain", Oncogene 19, 5872-5883.
  • Yang, S.S., Van Aelst, L. and Bar-Sagi, D. (1995) "Differential interactions of human Sosl and Sos2 with Grb2", J. Biol. Chem. 270, 18212-18215.
  • Sastry, L., Lin, W, Wong, W.T., DiFiore, P.P., Scoppa, C.A. and King, C.R. (1995) "Quantitative analysis of Grb2-Sosl interaction: the N-terminal SH3 domain of Grb2 mediates affinity", Oncogene 11, 1107-1112.
  • Simon, I.A. and Schreiber, S.L. (1995) "Grb2 SH3 binding to peptides from Sos: evaluation of a general model for SH3-ligand interactions", Chem. Biol 2, 53-60.
  • Williamson, M.P. (1994) "The structure and function of proline- rich regions in proteins", Biochem J. 297, 249-260.
  • Li, N., Batzer, A., DaIy, R., Yajnik, V, Skolnik, E., Chardin, P., Bar-Sagi, D., Margolis, B. and Schlessinger, I. (1993) "Guanine- nucleotide-releasing factor hSos 1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling", Nature 363, 85-88.
  • Rozakis-Adcock, M., Fernley, R., Wade, I., Pawson, T. and Bowtell, D. (1993) "The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos 1 ", Nature 363, 83-85.
  • Goudreau, N., Cornille, F., Duchesne, M., Parker, P., Tocque, B., Garbay, C. and Roques, B.P. (1994) "NMR structure of the N- terminal SH3 domain of GRB2 and its complex with a proline-rich peptide from Sos", Nat. Struct. Biol 1, 898-907.
  • Terasawa, H., Kbhda, D., Hatanaka, H., Tsuchiya, S., Ogura, K., Nagata, K., Ishii, S., Mandiyan, V, Ullrich, A., Schlessinger, I., et al. (1994) "Structure of the N-terminal SH3 domain of GRB2 complexed with a peptide from the guanine nucleotide releasing factor Sos", Nat. Struct. Biol. 1, 891-897.
  • Sparks, A.B., Rider, I.E., Hoftman, N.G., Fowlkes, D.M., Quillam, L.A. and Kay, B.K. (1996) "Distinct ligand preferences of Src homology 3 domains from Src, Yes, AbI, Cortactin, p53bp2, PLCgamma, Gk, and Grb2", Proc. Natl Acad. Sci. USA 93, 1540-1544.
  • Posern, G., Zheng, J., Knudsen, B.S., Kardinal, C., Muller, K.B., Voss, J., Shishido, T., Cowbum, D., Cheng, G., Wang, B., Kruh, G.D., Burrell, S.K., lacobson, C.A., Lenz, D.M., Zamborelli, T.J., Adermann, K., Hanafusa, H. and Feller, S.M. (1998) "Development of highly selective SH3 binding peptides for Crk and CRKL which disrupt Crk-complexes with DOCK 180, SoS and C3G", Oncogene 16, 1903-1912.
  • Vidai, M, Montiel, J.L., Cussac, D., Cornille, E, Duchesne, M., Parker, E, Tocque, B., Roques, B.P. and Garbay, C. (1998) "Differential interactions of the growth factor receptor-bound protein 2 N-SH3 domain with son of sevenless and dynamin. Potential role in the Ras-dependent signaling pathway", J. Biol. Chan. 273, 5343-5348.
  • Cesareni, G., Panni, S., Nardelli, G. and Castagnoli, L. (2002) "Can we infer peptide recognition specificity mediated by SH3 domains?", FEES Lett. 513, 38-44.
  • Kohda, D., Terasawa, H., Ichikawa, S., Ogura, K., Hatanaka, H., Mandiyan, V, Ullrich, A., Schlessinger, J. and Inagaki, E (1994) "Solution structure and ligand-binding site of the carboxy-terminal SH3 domain of GRB2", Structure 2, 1029-1040.
  • Lim, W.A., Fox, R.O. and Richards, EM. (1994) "Stability and peptide binding affinity of an SH3 domain from the Caenorhabditis elegans signaling protein Sem-5", Protein Sei. 3, 1261-1266.
  • Oehrl, W., Kardinal, C., Ruf, S., Adermann, K., Groffen, J., Feng, G.S., Blenis, J., Tan, T.H. and Feller, S.M. (1998) "The germinal center kinase (GCK)-related protein kinases HPKl and KHS are candidates for highly selective signal transducers of Crk family adapter proteins", Oncogene 17, 1893-1901.
  • Carlier, M.F., Nioche, P., Broutin-L'Hermite, I., Boujemaa, R., Le Clainche, C., Egile, C., Garbay, C., Ducruix, A., Sansonetti, P. and Pantaloni, D. (2000) "GRB2 links signaling to actin assembly by enhancing interaction of neural Wiskott-Aldrich syndrome protein (N-WASp) with actin-related protein (ARP2/3) complex", J. Biol. Chem. 275, 21946-21952.
  • Nishida, M., Nagata, K., Hachimori, Y., Horiuchi, M., Ogura, K., Mandiyan, V, Schlessinger, J. and Inagaki, E (2001) "Novel recognition mode between Vav and Grb2 SH3 domains", EMBO J. 20, 2995-3007.
  • Oak, S.A., Russo, K., Petrucci, T.C. and Jarrett, H.W. (2001) "Mouse alphal-syntrophin binding to Grb2: further evidence of a role for syntrophin in cell signaling", Biochemistry 40, 11270-11278.
  • Sugiyama, Y., Tomoda, K., Tanaka, T., Arata, Y., Yoneda-Kato, N. and Kato, J. (2001) "Direct binding of the signal-transducing adaptor Grb2 facilitates down-regulation of the cyclin-dependent kinase inhibitor p27Kipl", J. Biol. Chem. 276, 12084-12090.
  • Kato, M., Miyazawa, K. and Kitamura, N. (2000) "A deubiquitinating enzyme UBPY interacts with the Src homology 3 domain of Hrs-binding protein via a novel binding motif PX(V/D(D/N)RXXKP", J. Biol. Chem. 275, 37481-37487.
  • Lock, L.S., Royal, I., Naujokas, M.A. and Park, M. (2000) "Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and independent recruitment of Gabi to receptor tyrosine kinases", J. Biol. Chem. 275, 31536-31545.
  • Lewitzky, M., Kardinal, C., Gehring, N.H., Schmidt, E.K., Konkol, B., Eulitz, M., Birchmeier, W, Schaeper, U. and Feller, S.M. (2001) "The C-terminal SH3 domain of the adapter protein Grb2 binds with high affinity to sequences in Gabi and SLP-76 which lack the SH3-typical P-x-x-P core motif, Oncogene 20, 1052-1062.
  • Sattler, M., Mohi, M.G., Pride, Y.B., Quinnan, L.R., Malouf, N.A., Podar, K., Gesbert, E, Iwasaki, H., Li, S., Van Etten, R.A., Gu, H., Griffin, I.D. and Neel, B.C. (2002) "Critical role for Gab2 in transformation by BCR/ABL", Cancer Cell 1, 479-492.
  • Feller, S.M., Wecklein, H., Lewitzky, M., Kibler, E. and Raabe, T. (2002) "SH3 domain-mediated binding of the Drk protein to Dos is an important step in signaling of Drosophila receptor tyrosine kinases", Mech. Den 116, 129-139.
  • Liu, Y and Rohrschneider, L.R. (2002) "The gift of Gab", FEBS Lett. 515, 1-7.
  • Tu, Z., Ninos, I.M., Ma, Z., Wang, J.W., Lemos, M.P., Desponts, C., Ghansah, T., Howson, J.M. and Kerr, W.G. (2001) "Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5-phosphatase isoform that partners with the Grb2 adapter protein", Blood 98, 2028-2038.
  • Liu, S.K., Fang, N., Koretzky, G.A. and McGlade, C.J. (1999) "The hematopoietic-specific adaptor protein gads functions in Tcell signaling via interactions with the SLP-76 and LAT adaptors", Curr. Biol. 9, 67-75.
  • Bourgin, C., Bourette, R.P., Arnaud, S., Liu, Y., Rohrschneider, L.R. and Mouchiroud, G. (2002) "Induced expression and association of the Mona/Gads adapter and Gab3 scaffolding protein during monocyte/macrophage differentiation", MoI. Cell. Biol 22, 3744-3756.
  • Liu, J., Campbell, M., Guo, I.Q., Lu, D., Xian, Y.M., Andersson, B.S. and Arlinghaus, R.B. (1993) "BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon", Oncogene 8, 101-109.
  • Pendergast, A.M., Quilliam, L.A., Cripe, L.D., Bassing, C.H., Dai, Z., Li, N., Batzer, A., Rabun, K.M., Der, C.J., Schlessinger, J., et al. (1993) "BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein", Cell 75, 175-185.
  • Tauchi, T., Boswell, H.S., Leibowitz, D. and Broxmeyer, H.E. (1994) "Coupling between p210 bcr-abl and She and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway", J. Exp. Med. 179, 167-175.
  • Puil, L., Liu, J., Gish, G., Mbamalu, G., Bowtell, D., Pelicci, P.C., Arlinghaus, R. and Pawson, T. (1994) "Bcr-Abl oncoproteins bind directiy to activators of the Ras signalling pathway", EMBO J. 13, 764-773.
  • Gishizky, M.L., Cortez, D. and Pendergast, A.M. (1995) "Mutant forms of growth factor-binding protein-2 reverse BCR-ABLinduced transformation", Proc. Natl Acad. Sci. USA 92, 10889-10893.
  • Goga, A., McLaughlin, I., Afar, D.E., Saffran, D.C. and Witte, O.N. (1995) "Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene", Cell 82, 981-988.
  • Million, R.P. and Van Etten, R.A. (2000) "The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase", Blood 96, 664-670.
  • Zhang, X., Subrahmanyam, R., Wong, R., Gross, A.W. and Ren, R. (2001) "The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferati ve disease in mice by Bcr-Abl", MoL Cell Biol. 21, 840-853.
  • He, Y., Wertheim, I.A., Xu, L., Miller, I.P., Karnell, F.G., Choi, J.K., Ren, R. and Pear, W.S. (2002) "The coiled-coil domain and Tyr177 of ber are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl", Blood 99, 2957-2968.
  • Purge, K.A., Zhang, Y.W and Vande Woude, G.F. (2000) "Met receptor tyrosine kinase: enhanced signaling through adapter proteins", Oncogene 19, 5582-5589.
  • Tari, A.M. and Lopez-Berestein, G. (2001) "GRB2: a pivotal protein in signal transduction", Semin. Oncol 28, 142-147.
  • Fretz, H., Furet, P., Garcia-Echeverria, C., Schoepfer, J. and Rahuel, J. (2000) "Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways", Curr. Pharm. Des. 6, 1777-1796.
  • Kessels, H.W, Ward, A.C. and Schumacher, T.N. (2002) "Specificity and affinity motifs for Grb2 SH2-ligand interactions", Proc. Natl Acad. Sci. USA 99, 8524-8529.
  • Lee, C.H., Kominos, D., Jacques, S., Margolis, B., Schlessinger, J., Shoelson, S.E. and Kuriyan, J. (1994) "Crystal structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase", Structure 2, 423-438.
  • Gay, B., Suarez, S., Caravatti, G., Furet, P., Meyer, T. and Schoepfer, J. (1999) "Selective GRB2 SH2 inhibitors as anti-Ras therapy", Int. J. Cancer 83, 235-241.
  • Gay, B., Suarez, S., Weber, C., Rahuel, J., Fabbro, D., Furet, P., Caravatti, G. and Schoepfer, J. (1999) "Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility", J. Biol. Chem. 274, 23311-23315.
  • Atabey, N., Gao, Y., Yao, Z.J., Breckenridge, D., Soon, L., Soriano, I.V., Burke, Jr., T.R. and Bottaro, D.P. (2001) "Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions", J. BM. Chan. 276, 14308-14314.
  • Chose, R., Shekhtman, A., Goger, M.J., Ii, H. and Cowbum, D. (2001) "A novel, specific interaction involving the Csk SH3 domain and its natural ligand", Nat. Struct. Biol 8, 998-1004.
  • Gorina, S. and Pavletich, N.P. (1996) "Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2", Science 274, 1001-1005.
  • Brazin, K.N., Pulton, D.B. and Andreotti, A.H. (2000) "A specific intermolecular association between the regulatory domains of a Tec family kinase", J. MoI. Biol 302, 607-623.
  • Brazin, K.N., Mallis, R.I., Pulton, D.B. and Andreotti, A.H. (2002) "Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A", Proc. Natl Acad. Sci. USA 99, 1899-1904.
  • Zamora-Leon, S.P., Lee, G., Davies, P. and Shafit-Zagardo, B. (2001) "Binding of Fyn to MAP-2c through an SH3 binding domain. Regulation of the interaction by ERK2", J. Biol. Chem. 276, 39950-39958.
  • Kardinal, C., Posern, G., Zheng, I., Knudsen, B.S., Moarefi, I. and Feller, S.M. (1999) "Rational development of cell-penetrating high affinity SH3 domain binding peptides that selectively disrupt the signal transduction of Crk family adapters. Amgen Peptide Technology Group", Ann. N.Y. Acad. Sci. 886, 289-292.
  • Schumacher, T.N., Mayr, L.M., Minor, Ir., D.L., Milhollen, M.A., Burgess, M.W. and Kim, P.S. (1996) "Identification of D-peptide ligands through mirror-image phage display", Science 271, 1854-1857.
  • Kreil, G. (1997) "D-amino acids in animal peptides", Annu. Rev. Biochem. 66, 337-345.
  • Bowtell, D., Fu, P., Simon, M. and Senior, P. (1992) "Identification of murine homologues of the Drosophila son of sevenless gene: potential activators of ras", Proc. Natl Acad. Sci. USA 89, 6511-6515.
  • Wittekind, M., Mapelli, C, Farmer, 2nd, B.T., Suen, K.L., Goldfarb, V, Tsao, I., Lavoie, T, Barbacid, M., Meyers, C.A. and Mueller, L. (1994) "Orientation of peptide fragments from Sos proteins bound to the N-terminal SH3 domain of Grb2 determined by NMR spectroscopy", Biochemistry 33, 13531-13539.
  • Derossi, D., Chassaing, G. and Prochiantz, A. (1998) 'Trojan peptides: the penetratin system for intracellular delivery", Trends Cell Biol. 8, 84-87.
  • Dhut, S., Chaplin, T. and Young, B.D. (1990) "BCR-ABL and BCR proteins: biochemical characterization and localization", Leukemia 4, 745-750.
  • Derossi, D., Calvet, S., Trembleau, A., Brunissen, A., Chassaing, G. and Prochiantz, A. (1996) "Cell intemalization of the third helix of the Antennapedia homeodomain is receptor-independent", J. Biol. Chem. 271, 18188-18193.
  • Feller, S.M., Knudsen, B. and Hanafusa, H. (1995) "Cellular proteins binding to the first Src homology 3 (SH3) domain of the proto-oncogene product c-Crk indicate Crk-specific signaling pathways", Oncogene 10, 1465-1473.
  • Schulz, A., Adermann, K., Eulitz, M., Feller, S.M. and Kardinal, C. (2000) "Preparation of disulfide-bonded polypeptide heterodimers by titration of thio-activated peptides with thiol-containing peptides", Tetrahedron 56, 3889-3891.
  • Nguyen, I.T., Turck, C.W., Cohen, F.E., Zuckermann, R.N. and Um, W.A. (1998) "Exploiting the basis of proline recognition by SH3 and WW domains: design of N-substituted inhibitors", Science 282, 2088-2092.
  • Nguyen, I.T., Porter, M., Amoui, M., Miller, W.T., Zuckermann, R.N. and Lim, WA. (2000) "Improving SH3 domain ligand selectivity using a non-natural scaffold", Chem. Biol. 7,463-473.
  • Tuchscherer, G., Grell, D., Tatsu, Y, Durieux, P., FernandezCarneado, I., Hengst, B., Kardinal, C. and Feller, S.M. (2001) 'Targeting molecular recognition: exploring the dual role of functional pseudoprolines in the design of SH3 ligands", Angew. Chem. Int. Ed. 40, 2844-2848.
  • Lindgren, M., Hallbrink, M., Prochiantz, A. and Lange), U. (2000) "Cell-penetrating peptides", Trends Pharmacol. Sci. 21, 99-103.
  • Ho, A., Schwarze, S.R., Mermelstein, S.I., Waksman, G. and Dowdy, S.F. (2001) "Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo", Cancer Res. 61, 474-477.
  • Pooga, M, Soomets, U., Hallbrink, M, Valkna, A., Saar, K., Rezaei, K., Kahl, U., Hao, I.X., Xu, X.J., Wiesenfeld-Hallin, Z., Hokfelt, T., Bartfai, T. and Lange), U. (1998) "Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo", Nat. Biotechnol. 16, 857-861.
  • Morin, M.J. (2000) "From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and antiangiogenic agents", Oncogene 19, 6574-6583.
  • Zwick, E., Bange, J. and Ullrich, A. (2002) "Receptor tyrosine kinases as targets for anticancer drugs", Trends MoI. Med. 8, 17-23.
  • Tari, A.M., Hung, M.C., Li, K. and Lopez-Berestein, G. (1999) "Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells", Oncogene 18, 1325-1332.
  • Kairouz, R. and DaIy, R.J. (2000) "Tyrosine kinase signalling in breast cancer: modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates", Breast Cancer Res. 2, 197-202.
  • Lim, S.J., Lopez-Berestein, G., Hung, M.C., Lupu, R. and Tari, A.M. (2000) "Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells", Oncogene 19, 6271-6276.
  • Tip, S.S., Crew, A.J., Gee, J.M., Hui, R., Blarney, R.W., Robertson, I.F., Nicholson, R.I., Sutherland, R.L. and DaIy, R.J. (2000) "Upregulation of the protein tyrosine phosphatase SHP-I in human breast cancer and correlation with GRB2 expression", Int. J. Cancer 88, 363-368.
  • DaIy, R.J., Gu, H., Parmar, J., Malaney, S., Lyons, R.J., Kairouz, R., Head, D.R., Henshall, S.M., Neel, B.G. and Sutherland, R.L. (2002) "The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer", Oncogene 21, 5175-5181.
  • Cussac, D., Vidai, M., Leprince, C., Lin, W.Q., Cornille, F., Tiraboschi, G., Roques, B.P. and Garbay, C. (1999) "A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity", FASEB J. 13, 31-38.
  • Garbay, C., Liu, W.Q., Vidai, M. and Roques, B.P. (2000) "Inhibitors of Ras signal transduction as antitumor agents", Biochem. Pharmacol. 60, 1165-1169.
  • Dorsey, J.F., Jove, R., Kraker, A.J. and Wu, J. (2000) "The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210BcrAbI tyrosine kinase and induces apoptosis of K562 leukemic cells", Cancer Res. 60, 3127-3131.
  • Dorsey, J.F., Cunnick, J.M., Mane, S.M. and Wu, J. (2002) "Regulation of the Erk2-Elkl signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2", Blood 99, 1388-1397.
  • Rhee, S.G., Bae, Y.S., Lee, S.R. and Kwon, J. (2000) "Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation", Sci. STKE 2000, PEl.
  • Meng, T.C., Fukada, T. and Tonks, N.K. (2002) "Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo", Mol. CeIl. 9, 387-399.
  • Pasqualini, R. and Ruoslahti, E. (1996) "Organ targeting in vivo using phage display peptide libraries", Nature 380, 364-366.
  • Arap, W, Pasqualini, R. and Ruoslahti, E. (1998) "Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model", Science 279, 377-380.
  • Giordano, R.J., Cardo-Vila, M., Lahdenranta, J., Pasqualini, R. and Arap, W. (2001) "Biopanning and rapid analysis of selective interactive ligands", Nat. Med. 7, 1249-1253.
  • Trepel, M., Arap, W. and Pasqualini, R. (2001) "Modulation of the immune response by systemic targeting of antigens to lymph nodes", Cancer Res. 61, 8110-8112.
  • Arap, W, Haedicke, W, Bernasconi, M., Kain, R., Rajotte, D., Krajewski, S., Ellerby, H.M., Bredesen, D.E., Pasqualini, R. and Ruoslahti, E. (2002) 'Targeting the prostate for destruction through a vascular address", Proc. Natl Acad. Sci. USA 99, 1527-1531.
  • Essler, M. and Ruoslahti, E. (2002) "Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature", Proc. Natl Acad. Sci. USA 99, 2252-2257.
  • Scita, G., Nordstrom, J., Carbone, R., Tenca, P., Giardina, G., Gutkind, S., Bjamegard, M., Betsholtz, C. and Di Fiore, P.P. (1999) "EPS8 and E3B1 transduce signals from Ras to Rac", Nature 401, 290-293.
  • Scita, G., Tenca, P., Areces, L.B., Tocchetti, A., Frittoli, E., Giardina, G., Ponzanelli, I., Sini, P., Innocenti, M. and Di Fiore, RP. (2001) "An effector region in EpsS is responsible for the activation of the Rac-specific GEF activity of Sos-1 and for the proper localization of the Rac-based actin-polymerizing machine", J. CeIl. Biol. 154, 1031-1044.
  • Innocenti, M., Tenca, P., Frittoli, E., Faretta, M., Tocchetti, A., Di Fiore, R.P. and Scita, G. (2002) "Mechanisms through which Sos-1 coordinates the activation of Ras and Rac", J. Cell. Biol. 156, 125-136.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.